Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738510) titled 'Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Transfusions' on July 27.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Halia Therapeutics, Inc.

Condition: Myelodysplastic Syndromes Anemia

Intervention: Drug: Ofirnoflast

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 2026

Target Sample Size: 50

To know more, visit https://clinicaltrials.gov/study/NCT07738510

Disclaimer: Curated by ...